传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LEGN 传奇生物

休市中 12-20 16:00:00 EST

34.08

+0.06

+0.18%

盘后34.08

+0.000.00%

16:36 EST

最高34.89	最低33.76	成交量164.42万
今开34.35	昨收34.02	日振幅3.33%
总市值62.52亿	流通市值27.58亿	总股本1.83亿
成交额5,641万	换手率2.03%	流通股本8,093万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"LEGN","market":"US","secType":"STK","nameCN":"传奇生物","latestPrice":34.08,"timestamp":1734728400000,"preClose":34.02,"halted":0,"volume":1644206,"hourTrading":{"tag":"盘后","latestPrice":34.08,"preClose":34.08,"latestTime":"16:36 EST","volume":57629,"amount":1963995.18,"timestamp":1734730575564},"delay":0,"floatShares":80933390,"shares":183450503,"eps":-1.915937,"marketStatus":"休市中","marketStatusCode":7,"change":0.06,"latestTime":"12-20 16:00:00 EST","open":34.35,"high":34.888,"low":33.755,"amount":56414398.103768,"amplitude":0.033304,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.915937,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":1591329600000,"adjPreClose":34.02,"adrRate":2,"preHourTrading":{"tag":"盘前","latestPrice":34,"preClose":34.02,"latestTime":"09:28 EST","volume":210,"amount":7132.49943,"timestamp":1734704897306},"postHourTrading":{"tag":"盘后","latestPrice":34.08,"preClose":34.08,"latestTime":"16:36 EST","volume":57629,"amount":1963995.18,"timestamp":1734730575564},"volumeRatio":1.0804320293759522,"impliedVol":0.7318,"impliedVolPercentile":0.8611},"requestUrl":"/m/hq/s/LEGN/wiki","defaultTab":"wiki","newsList":[{"id":"2490861894","title":"传奇生物盘中异动 急速下挫5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490861894","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490861894?lang=zh_cn&edition=full","pubTime":"2024-12-11 23:18","pubTimestamp":1733930320,"startTime":"0","endTime":"0","summary":"北京时间2024年12月11日23时18分，传奇生物股票出现波动，股价大幅跳水5.44%。截至发稿，该股报35.84美元/股，成交量21.8315万股，换手率0.12%，振幅5.65%。机构评级方面，在所有26家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。传奇生物股票所在的生物技术行业中，整体跌幅为0.42%。传奇生物公司简介：Legend Biotech Corp是一家临床阶段的生物制药公司。该公司的收入来自许可证和协作收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121123184095e8fa59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121123184095e8fa59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LEGN","BK4505","BK4585","BK4139"],"gpt_icon":0},{"id":"2490127840","title":"传奇生物盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490127840","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490127840?lang=zh_cn&edition=full","pubTime":"2024-12-10 23:22","pubTimestamp":1733844176,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日23时22分，传奇生物股票出现异动，股价大幅下挫5.02%。截至发稿，该股报39.54美元/股，成交量12.165万股，换手率0.07%，振幅5.19%。机构评级方面，在所有26家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。传奇生物股票所在的生物技术行业中，整体跌幅为1.28%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210232256984b0ebb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210232256984b0ebb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","BK4588","BK4505","LEGN"],"gpt_icon":0},{"id":"2490940064","title":"金斯瑞生物科技(01548)：传奇生物宣布于2024年ASH年会上公布报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2490940064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490940064?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:14","pubTimestamp":1733822078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 发布公告，于2024年12月10日，传奇生物科技股份有限公司已发布新闻稿，公布了3期研究CARTITUDE-4最新数据。MRD阴性率是多发性骨髓瘤患者生存期延长的重要预后标志。MRD阴性率的研究结果已在加利福尼亚州圣地牙哥举行的第66届美国血液学会年会暨展览会上以口头报告的形式发表。研究进行了随机分组，208名患者接受CARVYKTI治疗，211名患者接受标准疗法。截至目前，CARVYKTI已在全球五个国家推出，治疗患者人数逾4500名。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","HK0000320223.HKD","01548","BK4139","BK4585","ASH","BK4588","HK0000306701.USD","BK1576","BK4505","BK4109","HK0000320264.USD","LEGN","BK1141","HK0000306685.HKD","BK1583"],"gpt_icon":0},{"id":"2490864365","title":"2024 ASH | 与标准治疗相比，CARVYKTI® 显著提高了复发或难治性多发性骨髓瘤患者MRD阴性率","url":"https://stock-news.laohu8.com/highlight/detail?id=2490864365","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490864365?lang=zh_cn&edition=full","pubTime":"2024-12-10 13:16","pubTimestamp":1733807760,"startTime":"0","endTime":"0","summary":"\" 3期研究CARTITUDE-4评估了CARVYKTI与PVd 或 DPd 的标准疗法在既往接受过一至三线治疗且来那度胺耐药的复发或难治性多发性骨髓瘤成人患者中的疗效。研究进行了随机分组，208名患者接受CARVYKTI治疗，211名患者接受标准治疗。此外，经CARVYKTI 治疗的患者迅速达到了较高的总体MRD阴性率，在第56天时，69%的可评估患者已达到MRD阴性。截至目前，我们已在全球五个国家推出了CARVYKTI，治疗患者人数逾4500名。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4576011_ZH76011_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2463526074.USD","BK4585","BK4139","ASH","BK4588","BK4505","LEGN","BK4109"],"gpt_icon":0},{"id":"2490773319","title":"传奇生物盘中异动 早盘股价大涨5.27%报43.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490773319","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490773319?lang=zh_cn&edition=full","pubTime":"2024-12-09 22:36","pubTimestamp":1733755008,"startTime":"0","endTime":"0","summary":"北京时间2024年12月09日22时36分，传奇生物股票出现波动，股价急速拉升5.27%。截至发稿，该股报43.73美元/股，成交量2.4992万股，换手率0.01%，振幅2.67%。传奇生物股票所在的生物技术行业中，整体涨幅为0.31%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Sonnet Biotherapeutics Holdings, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Sonnet Biotherapeutics Holdings, Inc.、Dermata Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为2927.01%、24.18%、22.39%，振幅较大的相关个股有Passage Bio, Inc.、Nkgen Biotech, Inc.、Sage Therapeutics, Inc.，振幅分别为107.52%、104.58%、102.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209223648ab6a0ca2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209223648ab6a0ca2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","BK4588","BK4585","LEGN"],"gpt_icon":0},{"id":"2486803373","title":"传奇生物盘中异动 早盘快速拉升5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486803373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486803373?lang=zh_cn&edition=full","pubTime":"2024-11-25 22:57","pubTimestamp":1732546679,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日22时57分，传奇生物股票出现波动，股价快速拉升5.23%。截至发稿，该股报43.08美元/股，成交量18.9793万股，换手率0.10%，振幅4.15%。机构评级方面，在所有24家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。传奇生物股票所在的生物技术行业中，整体涨幅为1.53%。该公司的收入来自许可证和协作收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112522580098e446c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112522580098e446c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LEGN","BK4505","BK4585","BK4139"],"gpt_icon":0},{"id":"2484148244","title":"传奇生物盘中异动 急速拉升5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484148244","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484148244?lang=zh_cn&edition=full","pubTime":"2024-11-20 22:51","pubTimestamp":1732114310,"startTime":"0","endTime":"0","summary":"北京时间2024年11月20日22时51分，传奇生物股票出现异动，股价急速拉升5.29%。截至发稿，该股报40.43美元/股，成交量16.4687万股，换手率0.09%，振幅4.92%。传奇生物股票所在的生物技术行业中，整体涨幅为0.22%。其相关个股中，Silexion Therapeutics Corp、Klotho Neurosciences Inc C/Wts 21/06/2029 、Forte Biosciences, Inc.涨幅较大，Silexion Therapeutics Corp、Forte Biosciences, Inc.、Tonix Pharmaceuticals Holding Corp.较为活跃，换手率分别为874.54%、341.77%、150.53%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Silexion Therapeutics Corp，振幅分别为163.37%、65.87%、56.10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120225150971a7b33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120225150971a7b33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","LEGN","BK4505","BK4585"],"gpt_icon":0},{"id":"2484077906","title":"技术变革打破竞争格局 全球大型医药企业并购潮涌","url":"https://stock-news.laohu8.com/highlight/detail?id=2484077906","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484077906?lang=zh_cn&edition=full","pubTime":"2024-11-19 01:48","pubTimestamp":1731952080,"startTime":"0","endTime":"0","summary":"今年以来，国内外创新药企并购加速，国内外已经发生多起医药领域收购事件。“并购六条”发布后，截至11月15日，A股已有超过110家上市公司公布了重大重组事件或相关进展。历史数据显示，全球创新药收入的大约三分之一来自企业“内部研发”的产品，而另外三分之二则来自于并购与合作。全球前20名的大型药企目前处于临床阶段的产品数量中，平均有55%来自“内部研发”，另外45%来自“外部创新”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-11-19/doc-incwpine6651299.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-19/doc-incwpine6651299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK4588","BK4139","BK1515","BK4585","BK4505","BK1161","LEGN","BK1574"],"gpt_icon":0},{"id":"2483355616","title":"高瓴HHLR三季度持仓：加仓中概趋势明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2483355616","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483355616?lang=zh_cn&edition=full","pubTime":"2024-11-15 06:00","pubTimestamp":1731621643,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BABA","LU0329678337.USD","LU0572944931.SGD","LU0823397285.USD","LU2778985437.USD","LU2257852520.SGD","LU0106252389.USD","688235","BK4548","FUTU","06160","LU2039709279.SGD","TCOM","LU0251143458.SGD","NTES","IE0008369823.USD","TTTN","BK4554","LU1226287529.USD","BK4524","PDD","09999","LU0594300419.USD","LU0737861772.HKD","LEGN","LU1688375341.USD","LU0456846285.SGD","LU0326950275.SGD","LU1720050803.USD","BK1587","09988","LU0593848301.USD","BK4538","BK4577","LU1105468828.SGD","LU0509642566.USD","09961","LU0011963245.USD","BEKE","LU0348805143.USD","BGNE","NQmain","LU0269904917.USD","LU1008478684.HKD","BK4501","LU1226287875.USD","VIPS","BK4558","BK1531","LU0327786744.USD"],"gpt_icon":0},{"id":"2483809019","title":"【港股通】金斯瑞生物科技跌3.85% 旗下传奇生物Q3净亏损1.253亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483809019","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483809019?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:57","pubTimestamp":1731466627,"startTime":"0","endTime":"0","summary":"金吾财讯 | 金斯瑞生物科技 股价受压，截止发稿，跌3.85%，报10.5港元，成交额7631万港元。消息面上，金斯瑞生物科技公布传奇生物2024年第三季度业绩，CARVYKTI净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长53.2%。净亏损为1.253亿美元，2023年同期为6220万美元。需要注意的是，日前，金斯瑞发布公告称，传奇生物的财务业绩不再合并入公司财务报表。该行预计，在净利润层面，2024年起金斯瑞将全面进入盈利区间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113105745abbbbce0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113105745abbbbce0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306685.HKD","BK1576","01548","BK1583","BK1141","HSTECH","HK0000320264.USD","LEGN","HK0000320223.HKD","HSCEI","HK0000306701.USD"],"gpt_icon":0},{"id":"2483151100","title":"港股异动 | 金斯瑞生物科技(01548)早盘跌近5% 传奇生物第三季度亏损扩大至1.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483151100","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483151100?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:39","pubTimestamp":1731465568,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技早盘跌近5%，截至发稿，跌4.4%，报10.44港元，成交额6556.92万港元。消息面上，金斯瑞生物科技公布传奇生物2024年第三季度业绩，CARVYKTI净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长53.2%。净亏损为1.253亿美元，2023年同期为6220万美元。值得注意的是，金斯瑞此前发布公告称，传奇生物的财务业绩不再合并入公司财务报表，公司将其视为对联营公司的投资。预计2024年起金斯瑞将全面进入盈利区间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1141","BK4588","HK0000320223.HKD","HK0000306685.HKD","BK1583","BK1576","HK0000306701.USD","BK4139","LEGN","BK4505","01548","HK0000320264.USD"],"gpt_icon":0},{"id":"2483406094","title":"传奇生物三季度净销售额达2.86亿美元 同比增87.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483406094","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483406094?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:17","pubTimestamp":1731460624,"startTime":"0","endTime":"0","summary":"财中社11月13日电金斯瑞生物科技（01548）发布了其联营公司传奇生物科技股份有限公司截至2024年9月30日的第三季度未经审计财务业绩。传奇生物在此期间的净贸易销售额约为2.86亿美元，同比增长87.6%，环比增长53.2%。其细胞疗法CARVYKTI?成为首个显著延长多发性骨髓瘤患者总生存期的疗法，并在多个国家获得了上市批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411133237911885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LEGN","BK4505","BK4585","BK4139"],"gpt_icon":0},{"id":"2483129066","title":"金斯瑞生物科技(01548)：传奇生物三季度合作收入为1.428亿美元，同比增长88.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483129066","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483129066?lang=zh_cn&edition=full","pubTime":"2024-11-13 06:20","pubTimestamp":1731450019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 公布传奇生物2024年第三季度业绩， CARVYKTI 净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长 53.2%。合作收入为1.428亿美元，同比增长88.14%，增长主要是由于与杨森协议有关的CARVYKTI销售收入增加。净亏损为1.253亿美元，2023年同期为6220万美元。截至2024年9月30日，现金及现金等价物和定期存款达到12亿美元，传奇生物认为这些资金将提供直至2026年的财务储备，传奇生物预计在 2026年实现经营利润。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4585","HK0000306701.USD","BK1141","BK4505","BK4588","HK0000306685.HKD","HK0000320264.USD","LEGN","HK0000320223.HKD","01548","BK1583","BK1576"],"gpt_icon":0},{"id":"2482701262","title":"传奇生物(LEGN.US)Q3营收同比增长66.9% 净亏损1.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482701262","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482701262?lang=zh_cn&edition=full","pubTime":"2024-11-12 21:10","pubTimestamp":1731417000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月12日美股盘前，传奇生物公布2024 年第三季度业绩。财报显示，传奇生物Q3营收1.6021亿美元，同比增长 66.9%；净亏损1.25亿美元，上年同期亏损为6220.7万美元；每股亏损为0.34美元，上年同期每股亏损为0.17美元。第三季度，传奇生物的许可收入为 1710 万美元，上年同期为 2010 万美元；合作收入为 1.428 亿美元，而上年同期为 7590 万美元。截至2024年9月30日的三个月，传奇生物的研发费用为9550万美元，而截至2023年9月30日的三个月为9590万美元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LEGN"],"gpt_icon":1},{"id":"2482898480","title":"传奇生物盘中异动 急速跳水5.01%报38.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482898480","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482898480?lang=zh_cn&edition=full","pubTime":"2024-11-09 01:06","pubTimestamp":1731085565,"startTime":"0","endTime":"0","summary":"北京时间2024年11月09日01时06分，传奇生物股票出现异动，股价大幅下跌5.01%。截至发稿，该股报38.90美元/股，成交量70.6539万股，换手率0.38%，振幅4.62%。传奇生物股票所在的生物技术行业中，整体涨幅为0.84%。解除合并传奇后，金斯瑞的经营层面利润将更准确地反映非细胞治疗业务情况。值得注意的是，金斯瑞生物竞品公司科济药业近日宣布其亮眼的临床数据，其中CT0590疗法的安全性可控，并在部分患者中实现了深度和持久的缓解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109010605971a56da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241109010605971a56da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4588","LEGN","BK4139","BK4585"],"gpt_icon":0},{"id":"2482648195","title":"联想生物技术公司预计每股亏损42美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2482648195","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482648195?lang=zh_cn&edition=full","pubTime":"2024-11-09 00:34","pubTimestamp":1731083663,"startTime":"0","endTime":"0","summary":"联想生物技术公司预计每股亏损42美分 - 财报前瞻传奇生物技术公司LEGN.OQLEGN.O11月12日公布的截至2024年9月30日的财报显示，该公司的季度收入预计将有所增长。LSEG分析师对传奇生物技术公司的平均预期是每股亏损42美分。11月8日 - 上一季度业绩。除非另有说明，所有数据均以美元为单位。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL4S3MF24P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEGN"],"gpt_icon":0},{"id":"2481191020","title":"港股异动 | 金斯瑞生物科技(01548)一度跌超7% 解除合并传奇生物 竞品公司临床数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2481191020","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481191020?lang=zh_cn&edition=full","pubTime":"2024-11-08 12:00","pubTimestamp":1731038436,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技一度跌超7%，截至发稿，跌6.34%，报10.94港元，成交额2.35亿港元。消息面上，金斯瑞此前公布，传奇生物的财务业绩不再合并入公司财务报表，公司将其视为对联营公司的投资。解除合并传奇后，金斯瑞的经营层面利润将更准确地反映非细胞治疗业务情况。预计2024 年起金斯瑞将全面进入盈利区间。据悉，今年上半年，金斯瑞生物仍亏损2.16亿美元，其中“细胞疗法板块”经调整经营亏损1.19亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK4585","LEGN","HK0000320223.HKD","BK1141","BK4505","01548","BK4139","BK1583","HK0000306701.USD","BK4588","HK0000320264.USD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2481625931","title":"传奇生物CARTITUDE-4四项研究成果即将亮相2024ASH年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2481625931","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481625931?lang=zh_cn&edition=full","pubTime":"2024-11-06 11:27","pubTimestamp":1730863620,"startTime":"0","endTime":"0","summary":"MRD阴性率是多发性骨髓瘤患者生存期延长的预后标志。CARVYKTI是首款且唯一获批用于治疗既往至少接受过一线治疗的多发性骨髓瘤患者的靶向BCMA CAR-T细胞疗法。在全球范围内，CARVYKTI目前已在五个国家上市，治疗患者已逾4000名。2022年2月，西达基奥仑赛获得美国食品药品监督管理","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4549251_ZH49251_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4505","BK4139","BK4588","BK4585","LEGN"],"gpt_icon":0},{"id":"2481836206","title":"金斯瑞生物科技(01548)：传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2481836206","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481836206?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:37","pubTimestamp":1730817421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 发布公告，于2024年11月5日，传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病阴性率的最新数据，该试验对比CARVYKTI与标准疗法针对多发性骨髓瘤患者的治疗。CARVYKTI是目前首个且唯一获批用于治疗既往至少接受过一线治疗的多发性骨髓瘤患者的靶向BCMA的CAR-T细胞疗法。CARVYKTI目前已在全球五个国家商业化，有超过4,000名患者使用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4139","HK0000306685.HKD","HK0000320223.HKD","HK0000306701.USD","BK1141","BK4505","BK4585","01548","BK4588","BK1576","HK0000320264.USD","LEGN","BK1583"],"gpt_icon":0},{"id":"2481826688","title":"金斯瑞生物科技：传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2481826688","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481826688?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:37","pubTimestamp":1730817421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金斯瑞生物科技 发布公告，于2024年11月5日，传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病阴性率的最新数据，该试验对比CARVYKTI与标准疗法针对多发性骨髓瘤患者的治疗。CARVYKTI是目前首个且唯一获批用于治疗既往至少接受过一线治疗的多发性骨髓瘤患者的靶向BCMA的CAR-T细胞疗法。CARVYKTI目前已在全球五个国家商业化，有超过4,000名患者使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105224308aba241d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105224308aba241d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306685.HKD","BK1576","01548","BK1583","BK1141","LEGN","HK0000320264.USD","HK0000320223.HKD","HK0000306701.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.legendbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.151},{"period":"3month","weight":-0.2978},{"period":"6month","weight":-0.2002},{"period":"1year","weight":-0.4324},{"period":"ytd","weight":-0.4336}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"传奇生物科技有限公司是一家全球性的临床级生物制药公司，致力于肿瘤和其他适应症的新药的发现和开发。该公司的差异化技术、全球开发和制造战略及专业知识使其能够针对高未满足需求的适应症生成、测试和制造下一代细胞疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.065278},{"month":2,"riseRate":0.5,"avgChangeRate":0.025486},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027354},{"month":4,"riseRate":0.75,"avgChangeRate":0.086701},{"month":5,"riseRate":0.5,"avgChangeRate":0.05248},{"month":6,"riseRate":1,"avgChangeRate":0.131481},{"month":7,"riseRate":0.6,"avgChangeRate":0.020473},{"month":8,"riseRate":0.2,"avgChangeRate":-0.044443},{"month":9,"riseRate":0.2,"avgChangeRate":-0.015767},{"month":10,"riseRate":0.4,"avgChangeRate":0.000994},{"month":11,"riseRate":0.4,"avgChangeRate":0.003857},{"month":12,"riseRate":0,"avgChangeRate":-0.075883}],"exchange":"NASDAQ","name":"传奇生物","nameEN":"Legend Biotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"传奇生物,LEGN,传奇生物股票,传奇生物股票老虎,传奇生物股票老虎国际,传奇生物行情,传奇生物股票行情,传奇生物股价,传奇生物股市,传奇生物股票价格,传奇生物股票交易,传奇生物股票购买,传奇生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"传奇生物(LEGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供传奇生物(LEGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}